Works matching AU Jagannath, Sundar

Results: 185
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect<sup>®</sup> MM Registry.

    Published in:
    British Journal of Haematology, 2021, v. 193, n. 1, p. 93, doi. 10.1111/bjh.17131
    By:
    • Abonour, Rafat;
    • Rifkin, Robert M.;
    • Gasparetto, Cristina;
    • Toomey, Kathleen;
    • Durie, Brian G. M.;
    • Hardin, James W.;
    • Terebelo, Howard R.;
    • Jagannath, Sundar;
    • Narang, Mohit;
    • Ailawadhi, Sikander;
    • Omel, James L.;
    • Lee, Hans C.;
    • Srinivasan, Shankar;
    • Kitali, Amani;
    • Agarwal, Amit;
    • Wagner, Lynne
    Publication type:
    Article
    15

    Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.

    Published in:
    EJHaem, 2022, v. 3, n. 1, p. 97, doi. 10.1002/jha2.312
    By:
    • Martin, Thomas;
    • Krishnan, Amrita;
    • Yong, Kwee;
    • Weisel, Katja;
    • Mehra, Maneesha;
    • Nair, Sandhya;
    • Qi, Keqin;
    • Londhe, Anil;
    • Diels, Joris;
    • Crivera, Concetta;
    • Jackson, Carolyn C.;
    • Olyslager, Yunsi;
    • Vogel, Martin;
    • Schecter, Jordan M.;
    • Banerjee, Arnob;
    • Valluri, Satish;
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Jagannath, Sundar
    Publication type:
    Article
    16

    Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma.

    Published in:
    EJHaem, 2021, v. 2, n. 1, p. 48, doi. 10.1002/jha2.120
    By:
    • Richardson, Paul G.;
    • Jagannath, Sundar;
    • Chari, Ajai;
    • Vogl, Dan T.;
    • Dimopoulos, Meletios A.;
    • Moreau, Philippe;
    • Dingli, David;
    • Wei, Lee‐Jen;
    • Richter, Joshua;
    • Biran, Noa;
    • Siegel, David;
    • Reichmann, William;
    • Li, Lingling;
    • Tang, Shijie;
    • Saint‐Martin, Jean‐Richard;
    • Joshi, Anita;
    • Kauffman, Michael;
    • Shah, Jatin;
    • Shacham, Sharon;
    • Lonial, Sagar
    Publication type:
    Article
    17

    Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.

    Published in:
    Clinical Drug Investigation, 2022, v. 42, n. 1, p. 29, doi. 10.1007/s40261-021-01100-y
    By:
    • Weisel, Katja;
    • Martin, Thomas;
    • Krishnan, Amrita;
    • Jagannath, Sundar;
    • Londhe, Anil;
    • Nair, Sandhya;
    • Diels, Joris;
    • Vogel, Martin;
    • Schecter, Jordan M.;
    • Banerjee, Arnob;
    • Berdeja, Jesus G.;
    • Nesheiwat, Tonia;
    • Garrett, Ashraf;
    • Qi, Keqin;
    • Valluri, Satish;
    • Usmani, Saad Z.;
    • Yong, Kwee
    Publication type:
    Article
    18
    19
    20

    Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the Connect® MM Registry.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2025, v. 25, n. 12, p. 58, doi. 10.1016/j.clml.2024.11.001
    By:
    • Terebelo, Howard R.;
    • Omel, James;
    • Wagner, Lynne I.;
    • Hardin, James W.;
    • Rifkin, Robert M.;
    • Ailawadhi, Sikander;
    • Durie, Brian G. M.;
    • Narang, Mohit;
    • Toomey, Kathleen;
    • Gasparetto, Cristina J.;
    • Joshi, Prashant;
    • Yu, Edward;
    • Flick, E. Dawn;
    • Ying-Ming Jou;
    • Lee, Hans C.;
    • Abonour, Rafat;
    • Jagannath, Sundar
    Publication type:
    Article
    21

    The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect® MM Registry.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 10, p. e336, doi. 10.1016/j.clml.2024.05.021
    By:
    • Abonour, Rafat;
    • Lee, Hans C.;
    • Rifkin, Robert;
    • Ailawadhi, Sikander;
    • Omel, James;
    • Hardin, James W.;
    • Narang, Mohit;
    • Toomey, Kathleen;
    • Gasparetto, Cristina;
    • Wagner, Lynne I.;
    • Terebelo, Howard;
    • Mouro, Jorge;
    • Dhanasiri, Sujith;
    • Liu, Liang;
    • Yu, Edward;
    • Jagannath, Sundar
    Publication type:
    Article
    22
    23
    24
    25
    26

    Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 2, p. 112, doi. 10.1016/j.clml.2022.11.008
    By:
    • Lee, Hans C.;
    • Ramasamy, Karthik;
    • Weisel, Katja;
    • Abonour, Rafat;
    • Hardin, James W.;
    • Rifkin, Robert M.;
    • Ailawadhi, Sikander;
    • Terebelo, Howard R.;
    • Durie, Brian G.M.;
    • Tang, Derek;
    • Joshi, Prashant;
    • Liu, Liang;
    • Jou, Ying-Ming;
    • Che, Min;
    • Hernandez, Gabriela;
    • Narang, Mohit;
    • Toomey, Kathleen;
    • Gasparetto, Cristina;
    • Wagner, Lynne I.;
    • Jagannath, Sundar
    Publication type:
    Article
    27
    28
    29

    Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 9, p. 690, doi. 10.1016/j.clml.2022.04.025
    By:
    • Weisel, Katja;
    • Krishnan, Amrita;
    • Schecter, Jordan M.;
    • Vogel, Martin;
    • Jackson, Carolyn C.;
    • Deraedt, William;
    • Yeh, Tzu-min;
    • Banerjee, Arnob;
    • Yalniz, Fevzi;
    • Nesheiwat, Tonia;
    • Sanden, Suzy Van;
    • Diels, Joris;
    • Valluri, Satish;
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Jagannath, Sundar;
    • Martin, Tom
    Publication type:
    Article
    30

    A New Reality for Multiple Myeloma Renal Failure: US Data Report on Kidney Transplant Outcomes.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 5, p. e314, doi. 10.1016/j.clml.2021.11.002
    By:
    • Costa, Luciano J.;
    • Lin, Yi;
    • Cornell, R. Frank;
    • Martin, Thomas;
    • Chhabra, Saurabh;
    • Usmani, Saad Z.;
    • Jagannath, Sundar;
    • Callander, Natalie S.;
    • Berdeja, Jesus G.;
    • Kang, Yubin;
    • Vij, Ravi;
    • Godby, Kelly N.;
    • Malek, Ehsan;
    • Neppalli, Amarendra;
    • Liedtke, Michaela;
    • Fiala, Mark;
    • Tian, Hong;
    • Valluri, Satish;
    • Marino, Jennifer;
    • Jackson, Carolyn C.
    Publication type:
    Article
    31
    32

    Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 3, p. 149, doi. 10.1016/j.clml.2021.08.007
    By:
    • Gasparetto, Cristina;
    • Jagannath, Sundar;
    • Rifkin, Robert M.;
    • Durie, Brian G.M.;
    • Narang, Mohit;
    • Terebelo, Howard R.;
    • Toomey, Kathleen;
    • Hardin, James W.;
    • Wagner, Lynne;
    • Ailawadhi, Sikander;
    • Omel, James L.;
    • Srinivasan, Shankar;
    • Dhalla, Mazaher;
    • Catamero, Donna;
    • Kitali, Amani;
    • Agarwal, Amit;
    • Abonour, Rafat
    Publication type:
    Article
    33
    34
    35

    NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S171, doi. 10.1016/S2152-2650(21)02367-3
    By:
    • Verina, Daniel;
    • Van Oekelen, Oliver;
    • Gleason, Charles;
    • Agte, Sarita;
    • Srivastava, Komal;
    • Beach, Katherine;
    • Aleman, Adolfo;
    • Mouhieddine, Tarek;
    • Chari, Ajai;
    • Cordon-Cardo, Carlos;
    • Krammer, Florian;
    • Jagannath, Sundar;
    • Simon, Viviana;
    • Wajnberg, Ania;
    • Parekh, Samir
    Publication type:
    Article
    36

    P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
    By:
    • Lonial, Sagar;
    • Berdeja, Jesus G.;
    • Dimopoulos, Meletios-Athanasios;
    • Jagannath, Sundar;
    • Knop, Stefan;
    • Hang Quach;
    • Rodríguez-Otero, Paula;
    • Richardson, Paul G.;
    • Sorrell, April;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • Tuong Vi Nguyen;
    • Hong, Kevin;
    • Peluso, Teresa;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    37

    P-136: Health-related quality of life (HRQL) among real-world Ide-Cel–eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect® MM registry.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S109, doi. 10.1016/S2152-2650(21)02263-1
    By:
    • Wagner, Lynne;
    • Abonour, Rafat;
    • Ailawadhi, Sikander;
    • Durie, Brian G.M.;
    • Gasparetto, Cristina J.;
    • Hardin, James W.;
    • Lee, Hans;
    • Narang, Mohit;
    • Rifkin, Robert;
    • Terebelo, Howard;
    • Toomey, Kathleen;
    • Joshi, Prashant;
    • Agarwal, Amit;
    • Braverman, Julia;
    • Dhanda, Devender S.;
    • Mia He;
    • Jagannath, Sundar
    Publication type:
    Article
    38
    39
    40
    41

    P-063: Pathogenic germline variants in hereditary cancer genes in patients with Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S73, doi. 10.1016/S2152-2650(21)02197-2
    By:
    • Thibaud, Santiago;
    • Etra, Aaron;
    • Subaran, Ryan;
    • Soens, Zachry;
    • Newman, Scott;
    • Rong Chen;
    • Chari, Ajai;
    • Cho, Hearn Jay;
    • Jagannath, Sundar;
    • Madduri, Deepu;
    • Melnekoff, David;
    • Richard, Shambavi;
    • Richter, Joshua;
    • Sanchez, Larysa;
    • Kuan-Lin Huang;
    • Lagana, Alessandro;
    • Parekh, Samir;
    • Onel, Kenan
    Publication type:
    Article
    42
    43

    OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S30, doi. 10.1016/S2152-2650(21)02122-4
    By:
    • Oekelen, Oliver Van;
    • Agte, Sarita;
    • Gleason, Charles;
    • Srivastava, Komal;
    • Beach, Katherine;
    • Aleman, Adolfo;
    • Upadhyaya, Bhaskar;
    • Kappes, Katerina;
    • Mouhieddine, Tarek;
    • Bo Wang;
    • Chari, Ajai;
    • Cordon-Cardo, Carlos;
    • Krammer, Florian;
    • Jagannath, Sundar;
    • Simon, Viviana;
    • Wajnberg, Ania;
    • Parekh, Samir
    Publication type:
    Article
    44

    OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
    By:
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Popat, Rakesh;
    • Stadtmauer, Edward A.;
    • Larsen, Jeremy T.;
    • Oriol, A.;
    • Knop, Stefan;
    • Jagannath, Sundar;
    • Cook, Gordon;
    • Badros, Ashraf Z.;
    • Rodríguez-Otero, Paula;
    • Siegel, David S.;
    • Tuong Vi Nguyen;
    • Micco, Antonia Di;
    • Amin, Alpesh;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    45

    OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02101-7
    By:
    • Anderson, Jr., Larry D.;
    • Nina Shah;
    • Jagannath, Sundar;
    • Berdeja, Jesus G.;
    • Lonial, Sagar;
    • Raje, Noopur;
    • Siegel, David S.;
    • Yi Lin;
    • Moreau, Philippe;
    • Yakoub-Agha, Ibrahim;
    • Delforge, Michel;
    • Einsele, Hermann;
    • Goldschmidt, Hartmut;
    • Weisel, Katja;
    • Cavo, Michele;
    • Reece, Donna E.;
    • Rambaldi, Alessandro;
    • Truppel-Hartmann, Anna;
    • Patel, Payal;
    • Liping Huang
    Publication type:
    Article
    46

    OAB-024: Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02098-X
    By:
    • Jagannath, Sundar;
    • Berdeja, Jesus G.;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam;
    • Madduri, Deepu;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C.;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Pacaud, Lida;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Usmani, Saad Z.
    Publication type:
    Article
    47

    MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S422, doi. 10.1016/S2152-2650(21)01946-7
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    48

    Poster: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01569-X
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    49

    Oral Abstract: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01275-1
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Yi Lin;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    50